Accueil/Actions/AUTL

AUTL

USD

Autolus Therapeutics plc American Depositary Share

$1.410-0.110 (-7.237%)

Prix en Temps Réel

Healthcare

Biotechnologie

Royaume-Uni

Graphique des Prix

Loading Chart...

Métriques Clés

Métriques de Marché

Fondamentaux de l'Entreprise

Statistiques de Trading

Métriques de Marché

Ouverture

$1.520

Haut

$1.535

Bas

$1.400

Volume

2.28M

Fondamentaux de l'Entreprise

Capitalisation Boursière

375.3M

Industrie

Biotechnologie

Pays

United Kingdom

Statistiques de Trading

Volume Moyen

3.73M

Bourse

NMS

Devise

USD

Intervalle sur 52 Semaines

Bas $1.105Actuel $1.410Haut $4.12

Actualités Connexes

3 nov. 2025 · 17:14

Analyst Upgrades

Needham Reiterates Buy on Autolus Therapeutics, Maintains $10 Price Target

Needham analyst Gil Blum reiterates Autolus Therapeutics with a Buy and maintains $10 price target.

Needham Reiterates Buy on Autolus Therapeutics, Maintains $10 Price Target

3 nov. 2025 · 14:05

GlobeNewswire

Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2025

LONDON and GAITHERSBURG, Md., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation

Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2025

27 oct. 2025 · 11:00

GlobeNewswire

Autolus Therapeutics Presents Clinical Data Updates at the American College of Rheumatology Convergence 2025

Data from the Phase 1 CARLYSLE study in severe refractory systemic lupus erythematosus (srSLE) suggests obe-cel is well tolerated with no ICANS or high-grade CRS; 50 million cell dose selected for Phase 2 pivotal